<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05045937</url>
  </required_header>
  <id_info>
    <org_study_id>Ivermectin Treatment Study #1</org_study_id>
    <nct_id>NCT05045937</nct_id>
  </id_info>
  <brief_title>Observational Study on the Use of Ivermectin as an Outpatient Treatment Option for COVID-19</brief_title>
  <official_title>Ivermectin Will be Used as an Outpatient Treatment Option for COVID-19 Patients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Patrick Robinson</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Patrick Robinson MD LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Ivermectin is currently being utilized by a number of physicians in the local area. My&#xD;
      objective will be to enroll these patients at the time of their evaluation for COVID-19&#xD;
      infection and to follow their progress through their recovery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients at local physician clinics as well as my own clinic will be enrolled at the time&#xD;
      they are evaluated for having COVID-19. Patients enrollment will be voluntary and based upon&#xD;
      their request for treatment with Ivermectin. These patients will be questioned on symptoms&#xD;
      and the timing of those symptoms in detail. They will then be followed throughout their&#xD;
      treatment course to evaluate their recovery experience. Detailed accounts of their symptoms&#xD;
      and their resolution will be followed. The study patients will stop being followed when they&#xD;
      are either admitted to the hospital or are deemed to be symptom free. Any other medications&#xD;
      prescribed to the patients will also be tracked. Medical histories will be taken and&#xD;
      documented to make comparisons at the end of the study. Those patients not requesting&#xD;
      Ivermectin will also be followed for comparisons at a later date.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 20, 2021</start_date>
  <completion_date type="Anticipated">September 20, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 20, 2023</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>4 Weeks</target_duration>
  <primary_outcome>
    <measure>Complete recovery from COVID-19 with resolution of symptoms</measure>
    <time_frame>4-6 weeks per individual</time_frame>
    <description>This group recovered completely from COVID-19 and remained an outpatient throughout the duration of their illness.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Admission to a hospital for further advanced treatment</measure>
    <time_frame>4-6 weeks per individual</time_frame>
    <description>This group of patients was unable to recover at home and required hospital admission</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Covid19</condition>
  <condition>COVID-19 Pneumonia</condition>
  <condition>COVID-19 Respiratory Infection</condition>
  <condition>COVID-19 Acute Bronchitis</condition>
  <arm_group>
    <arm_group_label>COVID-19 patients treated with Ivermectin</arm_group_label>
    <description>This group of patients will be those who requested to be treated with Ivermectin and whom have been prescribed such by different physicians. This group may or may not include those treated with Monoclonal Antibodies or Remdesivir.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>COVID-19 patients declining Ivermectin and wanting traditional treatment</arm_group_label>
    <description>This group of patients will be those who do not request to be treated with Ivermerctin and who want to be treated with a more traditional, minimalist approach. This group may or may not include those treated with Monoclonal Antibodies or Remdesivir.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ivermectin</intervention_name>
    <description>Ivermectin treatment of outpatients dosing at 0.4mg/kg until recovered along with supplemental treatment using a multi-modal approach.</description>
    <arm_group_label>COVID-19 patients treated with Ivermectin</arm_group_label>
    <other_name>Vitamin C</other_name>
    <other_name>Vitamin D</other_name>
    <other_name>Quercetin</other_name>
    <other_name>Zinc</other_name>
    <other_name>Budesonide</other_name>
    <other_name>Aspirin</other_name>
    <other_name>Tylenol</other_name>
    <other_name>Ibuprofen</other_name>
    <other_name>IV Infusion</other_name>
    <other_name>Monoclonal Antibodies</other_name>
    <other_name>COVID Vaccine</other_name>
    <other_name>Melatonin</other_name>
    <other_name>Niacin</other_name>
    <other_name>Albuterol</other_name>
    <other_name>Remdesivir</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All individuals presenting to various health clinics who are COVID positive and requesting&#xD;
        treatment. Although the primary focus is on the effectiveness of Ivermectin for treatment,&#xD;
        those not requesting Ivermectin treatment will be followed in a separate group.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Between the ages of 12-110 years old&#xD;
&#xD;
          -  Has a recently completed COVID test&#xD;
&#xD;
          -  Symptomatic and seeking treatment&#xD;
&#xD;
          -  Willingness to participate and have follow-up&#xD;
&#xD;
          -  Able and willing to take medications and treatment suggestions from the physician&#xD;
&#xD;
        Exclusion Criteria: Lack of symptoms, uncertain of COVID-19 status, outside of age limits&#xD;
        for treatment&#xD;
&#xD;
          -  No recent COVID test results&#xD;
&#xD;
          -  Asymptomatic, even if COVID positive&#xD;
&#xD;
          -  Outside of acceptable age range&#xD;
&#xD;
          -  Meets criteria for hospital admission&#xD;
&#xD;
          -  Unwilling to participate in trial study or have follow-up&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Admitted under gender at birth</gender_description>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>110 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patrick r Robinson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Patrick Robinson MD LLC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Patrick R Robinson, MD</last_name>
    <phone>3862377150</phone>
    <email>mustang6374@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Dana M Robinson, RN</last_name>
    <phone>8132156247</phone>
    <email>dmvkar143@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Patrick Robinson MD LLC</name>
      <address>
        <city>San Antonio</city>
        <state>Florida</state>
        <zip>33576</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Patrick R Robinson, MD</last_name>
      <phone>386-237-7150</phone>
      <email>mustang6374@yahoo.com</email>
    </contact>
    <contact_backup>
      <last_name>Dana M Robinson, RN</last_name>
      <phone>8132156247</phone>
      <email>dmvkar143@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Dana M Robinson, RN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Şimşek Yavuz S, Ünal S. Antiviral treatment of COVID-19. Turk J Med Sci. 2020 Apr 21;50(SI-1):611-619. doi: 10.3906/sag-2004-145. Review.</citation>
    <PMID>32293834</PMID>
  </reference>
  <reference>
    <citation>Trivedi N, Verma A, Kumar D. Possible treatment and strategies for COVID-19: review and assessment. Eur Rev Med Pharmacol Sci. 2020 Dec;24(23):12593-12608. doi: 10.26355/eurrev_202012_24057. Review.</citation>
    <PMID>33336780</PMID>
  </reference>
  <results_reference>
    <citation>Kaur H, Shekhar N, Sharma S, Sarma P, Prakash A, Medhi B. Ivermectin as a potential drug for treatment of COVID-19: an in-sync review with clinical and computational attributes. Pharmacol Rep. 2021 Jun;73(3):736-749. doi: 10.1007/s43440-020-00195-y. Epub 2021 Jan 3. Review.</citation>
    <PMID>33389725</PMID>
  </results_reference>
  <results_reference>
    <citation>Khan MSI, Khan MSI, Debnath CR, Nath PN, Mahtab MA, Nabeka H, Matsuda S, Akbar SMF. Ivermectin Treatment May Improve the Prognosis of Patients With COVID-19. Arch Bronconeumol (Engl Ed). 2020 Dec;56(12):828-830. doi: 10.1016/j.arbres.2020.08.007. Epub 2020 Sep 24. English, Spanish.</citation>
    <PMID>33293006</PMID>
  </results_reference>
  <results_reference>
    <citation>Ahmed S, Karim MM, Ross AG, Hossain MS, Clemens JD, Sumiya MK, Phru CS, Rahman M, Zaman K, Somani J, Yasmin R, Hasnat MA, Kabir A, Aziz AB, Khan WA. A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness. Int J Infect Dis. 2021 Feb;103:214-216. doi: 10.1016/j.ijid.2020.11.191. Epub 2020 Dec 2.</citation>
    <PMID>33278625</PMID>
  </results_reference>
  <results_reference>
    <citation>Padhy BM, Mohanty RR, Das S, Meher BR. Therapeutic potential of ivermectin as add on treatment in COVID 19: A systematic review and meta-analysis. J Pharm Pharm Sci. 2020;23:462-469. doi: 10.18433/jpps31457.</citation>
    <PMID>33227231</PMID>
  </results_reference>
  <results_reference>
    <citation>Gupta D, Sahoo AK, Singh A. Ivermectin: potential candidate for the treatment of Covid 19. Braz J Infect Dis. 2020 Jul - Aug;24(4):369-371. doi: 10.1016/j.bjid.2020.06.002. Epub 2020 Jun 28.</citation>
    <PMID>32615072</PMID>
  </results_reference>
  <results_reference>
    <citation>Vallejos J, Zoni R, Bangher M, Villamandos S, Bobadilla A, Plano F, Campias C, Chaparro Campias E, Achinelli F, Guglielmone HA, Ojeda J, Medina F, Farizano Salazar D, Andino G, Ruiz Diaz NE, Kawerin P, Meza E, Dellamea S, Aquino A, Flores V, Martemucci CN, Vernengo MM, Martinez SM, Segovia JE, Aguirre MG. Ivermectin to prevent hospitalizations in patients with COVID-19 (IVERCOR-COVID19): a structured summary of a study protocol for a randomized controlled trial. Trials. 2020 Nov 24;21(1):965. doi: 10.1186/s13063-020-04813-1.</citation>
    <PMID>33234158</PMID>
  </results_reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 14, 2021</study_first_submitted>
  <study_first_submitted_qc>September 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 16, 2021</study_first_posted>
  <last_update_submitted>September 15, 2021</last_update_submitted>
  <last_update_submitted_qc>September 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Patrick Robinson MD LLC</investigator_affiliation>
    <investigator_full_name>Patrick Robinson</investigator_full_name>
    <investigator_title>Chief Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
    <mesh_term>Bronchitis</mesh_term>
    <mesh_term>Respiratory Tract Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Ivermectin</mesh_term>
    <mesh_term>Remdesivir</mesh_term>
    <mesh_term>Ibuprofen</mesh_term>
    <mesh_term>Budesonide</mesh_term>
    <mesh_term>Melatonin</mesh_term>
    <mesh_term>Albuterol</mesh_term>
    <mesh_term>Quercetin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Individual patient data may be shared at a later date once compiled.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

